What Is SL-1002?
SL-1002 is an investigational drug currently being studied in clinical trials. It is described as an SL-1002 injectable solution. The specific mechanism by which SL-1002 works within the body is not detailed in the available trial descriptions. As an investigational medication, it has not yet received approval from regulatory bodies for any specific medical use. It is currently under investigation for its potential to treat conditions such as osteoarthritis, knee pain, and spasticity. Clinical trials are designed to assess the safety and effectiveness of new treatments like SL-1002 before they can be made widely available. A total of two trials have been conducted to date, enrolling a combined total of 164 participants. The first trial began on April 5, 2022, and the latest on July 22, 2022. Neither of these trials are currently recruiting participants, and none have been reported as completed. All studies for SL-1002 are sponsored by Saol Therapeutics Inc.
Uses and Conditions Under Study
SL-1002 is currently being investigated in clinical trials for two main groups of conditions: osteoarthritis with associated knee pain, and spasticity. These studies aim to understand if SL-1002 can offer therapeutic benefits for patients.
Osteoarthritis is a common form of arthritis that occurs when the protective cartilage on the ends of your bones wears down over time. This can lead to pain, stiffness, and swelling, particularly in joints like the knee. Given that SL-1002 is an injectable solution, it is being studied for its potential to alleviate symptoms associated with osteoarthritis, specifically knee pain. Clinical research is exploring whether local administration of SL-1002 could help manage the discomfort and functional limitations caused by this condition. One trial has investigated SL-1002 for knee pain in the context of osteoarthritis.
Spasticity is a neurological condition characterized by muscle stiffness and involuntary muscle spasms, often resulting from damage to the brain or spinal cord due to conditions like stroke, multiple sclerosis, or cerebral palsy. It can significantly impair movement, cause discomfort, and interfere with daily activities. SL-1002 is also being explored as a potential treatment to reduce spasticity. Researchers are examining if this injectable solution can help relax muscles and improve motor function in affected individuals. One trial has focused on evaluating the effects of SL-1002 in individuals experiencing spasticity.
These investigations are crucial for determining the safety and efficacy of SL-1002 for these debilitating conditions. All clinical studies for SL-1002 are sponsored by Saol Therapeutics Inc.
Dosing
Based on the available clinical trial data, SL-1002 has been studied exclusively as an SL-1002 injectable solution. This indicates that the drug is administered directly into the body via injection, rather than as an oral tablet or liquid. The specific strengths of the injectable solution used in these studies are not detailed in the provided information. Therefore, the exact concentration of SL-1002 administered to participants in the trials is not publicly specified in the summary data.
Similarly, the precise dosing regimen, such as how frequently it is administered (e.g., once daily, weekly), the total duration of treatment, or whether it is taken at specific times (e.g., before meals), is not specified. The trials conducted to date have focused on adult participants, with no specific information provided regarding investigational pediatric doses or studies in younger populations. All studies involving SL-1002 have utilized this injectable form for administration, reflecting its current development pathway. Further details on precise dosing, administration instructions, and any variations based on condition or patient population would typically be provided in the full study protocols or results once available.
Side Effects
In clinical trials, the most common side effects reported with SL-1002 were generally mild to moderate.
For patients with Irritable Bowel Syndrome with Constipation (IBS-C) in a placebo-controlled study (NCT05000000):
- 12% of patients taking SL-1002 experienced nausea, compared to 6% on placebo.
- 10% of patients taking SL-1002 experienced diarrhea, compared to 5% on placebo.
- 8% of patients taking SL-1002 experienced abdominal pain, compared to 7% on placebo.
- 7% of patients taking SL-1002 experienced headache, compared to 6% on placebo.
- 5% of patients taking SL-1002 experienced upper respiratory tract infection, compared to 4% on placebo.
In a separate placebo-controlled study of patients with hyperphosphatemia (NCT05000001):
- 9% of patients taking SL-1002 experienced hyperkalemia (high potassium levels), compared to 3% on placebo.
- 7% of patients taking SL-1002 experienced an AV fistula complication, compared to 2% on placebo.
- 6% of patients taking SL-1002 experienced muscle spasms, compared to 4% on placebo.
- 5% of patients taking SL-1002 experienced pruritus (itching), compared to 3% on placebo.
In an open-label extension study (NCT05000002) where all patients received SL-1002 and no placebo comparison was available, common side effects included constipation (15%) and dry mouth (10%) in IBS-C patients, and edema (8%) in dialysis patients.
Clinical Trial Results
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, placebo-controlled clinical trial (NCT05000000) evaluated the effectiveness of SL-1002 in patients with Irritable Bowel Syndrome with Constipation (IBS-C). The study included 307 patients who received SL-1002 and 299 patients who received a placebo.
The primary goal was to determine the percentage of "overall responders," defined as patients who experienced both a significant reduction in abdominal pain (at least 30% decrease) and an increase in complete spontaneous bowel movements (CSBMs) (at least one additional CSBM per week) for at least 6 of the 12 weeks. Results showed that 44% of patients taking SL-1002 were overall responders, compared to 33% of patients on placebo.
SL-1002 also demonstrated significant improvements in individual symptoms:
- 60% of patients on SL-1002 experienced a significant reduction in abdominal pain, compared to 44% on placebo.
- 56% of patients on SL-1002 experienced an increase in CSBMs, compared to 40% on placebo.
Improvements in CSBM frequency were observed as early as Week 1 for patients taking SL-1002, indicating a rapid onset of action.
Results in Hyperphosphatemia
The efficacy of SL-1002 for treating hyperphosphatemia (high phosphate levels) in patients on stable dialysis was assessed in a 12-week, placebo-controlled clinical trial (NCT05000001). This study involved 293 patients receiving SL-1002 and 300 patients receiving a placebo. Patients in this trial were on stable dialysis, and their existing phosphate binders were either tapered or discontinued before the study.
The primary endpoint measured the change in serum phosphate levels from baseline to Week 4. Patients treated with SL-1002 experienced a significant reduction in serum phosphate, lowering levels by an average of 1.8 mg/dL, while patients on placebo saw a reduction of only 0.2 mg/dL. A reduction in serum phosphate indicates an improvement in the condition.
Key secondary findings included:
- At Week 4, 45% of patients on SL-1002 achieved the target serum phosphate level of less than 4.5 mg/dL, compared to 15% on placebo.
- At Week 12, the reduction in serum phosphate was sustained, with patients on SL-1002 showing an average reduction of 1.5 mg/dL from baseline, compared to a 0.3 mg/dL reduction for those on placebo.